Powder: -20°C for 3 years | In solvent: -80°C for 1 year
ARD-1676 is an orally administered androgen receptor (AR) PROTAC degrader that combines an AR ligand with a cereblon ligand. It demonstrates AR-degrading activity both in vitro and in vivo, and effectively inhibits VCaP tumor growth in mouse xenograft models [1].
説明 | ARD-1676 is an orally administered androgen receptor (AR) PROTAC degrader that combines an AR ligand with a cereblon ligand. It demonstrates AR-degrading activity both in vitro and in vivo, and effectively inhibits VCaP tumor growth in mouse xenograft models [1]. |
In vitro | ARD-1676 exhibits a DC50 for androgen receptor (AR) degradation at 0.1 nM in AR+ VCaP cells and 1.1 nM in LNCaP cell lines, while its IC50 values for inhibiting cell proliferation are 11.5 nM in VCaP and 2.8 nM in LNCaP cell lines [1]. |
In vivo | ARD-1676 exhibits oral bioavailability of 67%, 44%, 31%, and 99% in mice, rats, dogs, and monkeys, respectively. It effectively reduces AR (AR) protein levels in murine VCaP tumor tissues and inhibits tumor growth in the VCaP murine xenograft tumor model [1]. |
分子量 | 788.33 |
分子式 | C44H46ClN7O5 |
CAS No. | 2632305-36-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
ARD-1676 2632305-36-1 Endocrinology/Hormones PROTAC Androgen Receptor PROTACs Inhibitor inhibitor inhibit